Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Edgewise Therapeutics, Inc. Market Cap
The Edgewise Therapeutics, Inc. (EWTX) share price is expected to increase by 78.44% over the next year. This is based on calculating the average 12-month share price estimate provided by 0 stock analysts who have covered EWTX. Price targets range from $25 at the low end to $48 at the high end. The current analyst consensus for EWTX is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assigned EWTX 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Edgewise Therapeutics, Inc. to perform worse than the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on EWTX. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of EWTX.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Laura Chico Wedbush | Outperform | $31 | Reiterates | Aug 16, 2024 |
| Tessa Romero JP Morgan | Overweight | $31 | Maintains | Aug 12, 2024 |
| Leonid Timashev RBC Capital | Outperform | $32 | Reiterates | Jul 25, 2024 |
| Leonid Timashev RBC Capital | Outperform | $32 | Reiterates | Jul 10, 2024 |
| Tessa Romero JP Morgan | Overweight | $30 | Maintains | Jul 9, 2024 |
| Yasmeen Rahimi Piper Sandler | Overweight | $48 | Maintains | Jul 1, 2024 |
| Laura Chico Wedbush | Outperform | $31 | Reiterates | Jun 26, 2024 |
| Leonid Timashev RBC Capital | Outperform | $32 | Maintains | Apr 22, 2024 |
| Srikripa Devarakonda Truist Securities | Buy | $25 | Maintains | Apr 17, 2024 |
| Laura Chico Wedbush | Outperform | $26 | Reiterates | Apr 16, 2024 |
| Leonid Timashev RBC Capital | Outperform | $28 | Reiterates | Mar 12, 2024 |
| Yasmeen Rahimi Piper Sandler | Overweight | $48 | Initiates | Mar 7, 2024 |
| Laura Chico Wedbush | Outperform | $23 | Maintains | Nov 10, 2023 |
| Laura Chico Wedbush | Outperform | $27 | Reiterates | Aug 16, 2023 |
| Laura Chico Wedbush | Outperform | $27 | Reiterates | Aug 11, 2023 |
| Tessa Romero JP Morgan | Overweight | $25 | Maintains | Jun 30, 2023 |
| Leonid Timashev RBC Capital | Outperform | $28 | Reiterates | Jun 28, 2023 |
| Srikripa Devarakonda Truist Securities | Buy | $25 | Reiterates | Jun 28, 2023 |
| Srikripa Devarakonda Truist Securities | Buy | $25 | Reiterates | Jun 27, 2023 |
JP Morgan | Overweight | Maintains | Jun 20, 2023 |
When did it IPO
2021
Staff Count
97
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Kevin Koch Ph.D.
Market Cap
$1.85B
In 2023, EWTX generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that EWTX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 08 Aug 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Edgewise Therapeutics (Nasdaq: EWTX) reported Q2 2024 financial results, highlighting progress in cardiac and skeletal muscle programs, with updates on EDG-7500 and sevasemten expected soon.
Why It Matters - Edgewise Therapeutics' progress on key muscle disease programs and upcoming updates could influence stock performance and investor sentiment in the biopharmaceutical sector.
Mon, 05 Aug 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - Edgewise Therapeutics, founded in 2017, is advancing sevasemten in phase 3 trials for Becker Muscular Dystrophy, offering a competitive, genotype-agnostic treatment approach.
Why It Matters - Edgewise Therapeutics' sevasemten targets a niche market with a unique approach, potentially leading to significant returns as it advances in phase 3 trials amidst strong backing and management.
Tue, 30 Jul 2024
Sentiment - NEUTRAL
Source - InvestorPlace
Summary - Small-cap companies are high-risk investments but typically offer greater potential rewards for investors.
Why It Matters - Small-cap companies offer high-risk, high-reward opportunities, attracting investors seeking growth. Their performance can significantly impact portfolio returns and market dynamics.
Wed, 17 Jul 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Edgewise Therapeutics, Inc. (EWTX) is being evaluated for its potential as a strong stock choice for momentum investors. Further analysis will determine its suitability.
Why It Matters - The focus on Edgewise Therapeutics as a potential top stock for momentum investors signals possible strong price movements, influencing buy or sell decisions and portfolio strategies.
Fri, 10 May 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Edgewise Therapeutics, Inc. (Nasdaq: EWTX) will present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024, at 3:35 pm ET, with a live webcast available for replay.
Why It Matters - Management presentations at conferences often provide insights into company strategy, upcoming products, and financial performance, which can influence stock performance and investor sentiment.
Thu, 09 May 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Edgewise Therapeutics reported strong Q1 2024 financial results, highlighting progress in muscle disease programs and the initiation of the Phase 2 CIRRUS-HCM trial for EDG-7500.
Why It Matters - Edgewise Therapeutics' progress in muscle disease treatments and the initiation of a Phase 2 trial may signal potential growth and innovation, impacting future stock performance and investor sentiment.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
